Table 2 Examples of different sub-phenotypes derived from post hoc analyses of a randomized controlled trial (Angiotensin II for the Treatment of High-Output Shock-ATHOS-3-trial) [33]

Wieruszewski et al. [34] 3/18/2024 5:35:00 PM

Low NED (≤ 0.25 μg/kg/min) at baseline, n = 104

High NED (> 0.25 μg/kg/min), n = 217

In patients receiving low NED at randomization, administration of AT II was associated with lower 28-day mortality (HR 0.509; 95% CI 0.274–0.945, p = 0.03), while no difference was observed in the high-NED subgroup (HR 0.933; 95% CI 0.644–1.350, p = 0.71)

0.21 (0.18–0.23) μg/kg/min in the low-NED group vs 0.47 (0.33–0.68) μg/kg/min in the high-NED group for patients in the AT II group

Bellomo et al. [37]

Low serum renin concentrations at baseline (below median), n = 127

High serum renin concentrations at randomization (above median), n = 128

In patients with high renin concentrations, treatment with AT II was associated with lower 28-day mortality (50.9%) compared to placebo (69.9%, unstratified hazard ratio, 0.56; 95% confidence interval, 0.35 to 0.88; p = 0.012)

0.36 (0.23–0.50) μg/kg/min in the high renin group treated with AT-2 vs 0.40 (0.29–0.69) μg/kg/min in the placebo group

Ham et al. [66]

Patients requiring ≤ 5 ng kg/min angiotensin II at 30 min

Patients receiving > 5 ng/kg/min angiotensin II at 30 min

Day 28 survival was higher in the ≤ 5 ng/kg/min subgroup versus the > 5 ng/kg/min subgroup (59% vs 33%, respectively; hazard ratio, 0.48 [95% CI 0.28–0.72], p = 0.0007)

0.52 (0.301) µg/kg/min (SD) in the low dose vs 0.45 (0.377) µg/kg/min (SD) in the high-dose group

Tumlin et al. [35]

Patient receiving RRT at study drug initiation (n = 45 AT II, n = 60 placebo)

–

In patients receiving RRT at study drug initiation, patients in the AT II group had higher 28-day survival vs placebo (unadjusted HR 0.52; 95% CI 0.30–0.87; p = 0.012)

0.46 (0.32–0.78) μg/kg/min in the placebo vs 0.36 (0.23–0.49) μg/kg/min in the AT II group